Diagnose cancers or tumours in the liver, a comprehensive procedure called as liver cancer diagnostics. First and foremost, a thorough evaluation of the patient's medical history and a physical examination to detect symptoms and risk factors are performed. Ultrasound, CT scans, and MRI can offer detailed images of the liver that can be used to detect anomalies and cancer features. Blood tests, which detect indications such as alpha-fetoprotein (AFP), are critical for both identifying and following the progression of liver cancer. A biopsy is essential to confirm the diagnosis of liver cancer if imaging or blood tests detect it. To be studied under a microscope, a small sample of liver tissue must be taken during a biopsy. Various biopsy procedures, such as guided needle, provide precise collection.
According to SPER market research, ‘Europe Liver Cancer Diagnostics Market Size- By Test Type, By Cancer Stages, By Cancer Type, By Product, By Technology, By Application, By Gender, By End User, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2033’ state that the Europe Liver Cancer Diagnostics Market is predicted to reach USD 3.11 billion by 2033 with a CAGR of 6.28%.
The European Liver Cancer Diagnostics Market has experienced tremendous growth as a result of a number of important factors. First off, there is a greater need for precise detection techniques due to the rising prevalence of liver cancer in the area. The prevalence of risk factors such alcoholism, hepatitis B and C infections, and non-alcoholic fatty liver disease (NAFLD) is on the rise, which has increased the risk of liver cancer.
The accuracy and effectiveness of identifying liver cancer have also grown because to developments in medical imaging technology. High-resolution imaging methods such as MRI, CT scans, and ultrasonography have enhanced the identification and characterization of liver tumours. Better treatment outcomes result from the early discovery and accurate staging provided by these imaging modalities for liver cancer.
Numerous issues will have an impact on the growth and effectiveness of the Europe Liver Cancer Diagnostics Market. The complexity of liver cancer is a first obstacle since it generally manifests with ambiguous symptoms, making early detection difficult. This delay in diagnosis may jeopardise the effectiveness of treatment alternatives, thereby impacting patient outcomes. The fact that liver cancer is frequently accompanied with other liver disorders such as cirrhosis complicates the diagnosis even further. Diagnostics for liver cancer may be too expensive. Because modern imaging procedures and biomarker testing are expensive, some people or healthcare systems may choose not to use them.
Impact of COVID-19 on Europe Liver Cancer Diagnostics Market
The market for liver diagnostics in Europe has been significantly impacted by the COVID-19 epidemic. Beginning with the disruption of healthcare systems and resources caused by the pandemic, conditions unrelated to COVID-19, such as the identification of liver cancer, were given less priority and attention. Due to an increase in patient load and the prioritization of COVID-19 care, which is delaying the diagnosis and treatment of liver cancer, many healthcare facilities are under stress.
Request For Free Sample Report @ https://www.sperresearch.com/report-store/europe-liver-cancer-diagnostics-market.aspx?sample=1
Europe Liver Cancer Diagnostics Market Key Players:
Furthermore, In December 2022, FUJIFILM Holdings America Corporation revealed a purchase agreement asset with Inspirata, Inc. to buy a digital pathology firm to extend its robust enterprise imaging portfolio. As a result, pathology images and data can be integrated into a healthcare organization's electronic health record system, streamlining treatment delivery for cancer patients. In addition, some of the market key players are; ABK Biomedical Inc., Agilent Technologies Inc., Altogen Biosystems, Diagnostic Biosystems Inc., Diazyme Laboratories Inc., Epigenomics AG, Others.
Europe Liver Cancer Diagnostics Market Key Segments Covered
The SPER Market Research report seeks to give market dynamics, demand, and supply forecasts for the years up to 2032. This report contains statistics on product type segment growth estimates and forecasts.
By Test Type: Based on the Test Type, Europe Liver Cancer Diagnostics Market is segmented as; Imaging Test, Biopsy, Genomic Test, and Others.
By Cancer Stages: Based on the Cancer Stages, Europe Liver Cancer Diagnostics Market is segmented as; Stage 0, Stage I, Stage II, Stage III, and Stage IV.
By Cancer Type: Based on the Cancer Type, Europe Liver Cancer Diagnostics Market is segmented as; Primary Liver Cancer and Secondary Liver Cancer.
By Product: Based on the Product, Europe Liver Cancer Diagnostics Market is segmented as; Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables.
By Technology: Based on the Technology, Europe Liver Cancer Diagnostics Market is segmented as; Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others.
By Application: Based on the Application, Europe Liver Cancer Diagnostics Market is segmented as; Screening, Diagnostic and Predictive, Prognostic, and Research.
By Gender: Based on the Gender, Europe Liver Cancer Diagnostics Market is segmented as; Female, Male.
By End User: Based on the End User, Europe Liver Cancer Diagnostics Market is segmented as; Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others.
By Distribution Channel: Based on the Distribution Channel, Europe Liver Cancer Diagnostics Market is segmented as; Direct Tender, Retail Sales, and Others.
By Region: This report also provides the data for key regional segments of Belgium, France, Germany, Italy, Netherlands, Norway, Russia, Spain, Switzerland, Turkey, U.K., Rest of Europe.
This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.
For More Information, refer to below link:-
Europe Liver Cancer Diagnostics Market Future Growth
Related Reports:
Follow Us –
LinkedIn | Instagram | Facebook | Twitter
Contact Us:
Sara Lopes, Business Consultant – U.S.A.
SPER Market Research
+1-347-460-2899
Fact.MR, in its recent study, projects the global liver cancer diagnostics market to register a steady expansion at 5.5% CAGR during the forecast period 2017 to 2022.
In 2017, the global market for liver cancer diagnostics is expected to reach nearly US$ 700 Mn in revenues.
In addition, liver cancer diagnostics markets in North America and Europe will exhibit expansion at similar CAGRs through 2022.Important regions covered in the liver cancer diagnostics market report include:North America (Canada, US)Latin America (Argentina, Mexico)Europe (NORDIC, UK)APEJ (China, India)The liver cancer diagnostics market report also provides data regarding the key countries in the defined regions.The fifth most prevalent cancer, liver cancer, caused 9.1% deaths among the overall population affected with cancer across the globe in 2012.
A slew of risk factors are associated with liver cancer including infection pertaining to hepatitis C virus (HCV), diabetes, obesity, diabetes, obesity, exposure to dietary aflatoxin, alcohol-induced cirrhosis, hepatitis B virus (HBV).
With the capability of modification of these risk factors, strong prospects have been offered to lower its prevalence and mortality, by utilizing preventive strategies such as lifestyle modification, and hepatitis immunization.
These factors are expected to fuel demand for liver cancer diagnostics across the globe.AFP test is projected to remain sought-after for liver cancer diagnostics over the forecast period.
